Maria M. Cainazzo

Modena, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Correction to: Monoclonal anti‑CGRP antibodies in post‑menopausal women: a real‑life study.

Correction to: Monoclonal anti‑CGRP antibodies in post‑menopausal women: a real‑life study.

Journal: Acta neurologica Belgica
Published: July 22, 2023

Cluster Headache Genomewide Association Study and Meta-Analysis Identifies Eight Loci and Implicates Smoking as Causal Risk Factor.

Cluster Headache Genomewide Association Study and Meta-Analysis Identifies Eight Loci and Implicates Smoking as Causal Risk Factor.

Journal: Annals of neurology
Published: March 01, 2023

Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study.

Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study.

Journal: Acta neurologica Belgica
Published: August 17, 2022

Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population.

Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population.

Journal: Brain and behavior
Published: July 20, 2022

Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study.

Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study.

Journal: Cephalalgia : an international journal of headache
Published: April 26, 2022

Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.

Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.

Journal: Cephalalgia : an international journal of headache
Published: February 09, 2022

Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.

Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: November 06, 2021

Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study.

Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study.

Journal: Pain medicine (Malden, Mass.)
Published: August 04, 2021

Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.

Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: April 26, 2021

Predictors of response to erenumab after 12 months of treatment.

Predictors of response to erenumab after 12 months of treatment.

Journal: Brain and behavior
Published: March 23, 2021

Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study.

Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: October 30, 2020

Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study.

Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study.

Journal: Cephalalgia : an international journal of headache
Published: April 30, 2020
Showing 1-12 of 25

Last Updated: 09/26/2026